These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31132016)

  • 21. Explanatory trials versus pragmatic trials.
    Sedgwick P
    BMJ; 2014 Nov; 349():g6694. PubMed ID: 25395503
    [No Abstract]   [Full Text] [Related]  

  • 22. What's Important: Patient Engagement in Research.
    Hale D; Marvel D; Wells J;
    J Bone Joint Surg Am; 2020 Oct; 102(20):1836-1838. PubMed ID: 33086354
    [No Abstract]   [Full Text] [Related]  

  • 23. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology.
    van Gestel AM; Anderson JJ; van Riel PL; Boers M; Haagsma CJ; Rich B; Wells G; Lange ML; Felson DT
    J Rheumatol; 1999 Mar; 26(3):705-11. PubMed ID: 10090187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria.
    Kingsley GH; Khoshaba B; Smith CM; Choy EH; Scott DL
    Rheumatology (Oxford); 2005 May; 44(5):629-32. PubMed ID: 15705630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T; Pincus T
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Supporting patient screening to identify suitable clinical trials.
    Bucur A; Van Leeuwen J; Chen NZ; Claerhout B; De Schepper K; Perez-Rey D; Alonso-Calvo R; Pugliano L; Saini K
    Stud Health Technol Inform; 2014; 205():823-7. PubMed ID: 25160302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The majority of patients with psoriatic arthritis are not eligible for randomised clinical trials.
    Runarsdottir EE; Gunnarsdottir AI; Love TJ; Gunnarsson PS; Gudbjornsson B;
    Clin Exp Rheumatol; 2018; 36(6):1068-1073. PubMed ID: 29998835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.
    Sokka T; Pincus T
    J Rheumatol; 2003 Jun; 30(6):1138-46. PubMed ID: 12784382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The accuracy and efficiency of electronic screening for recruitment into a clinical trial on COPD.
    Schmickl CN; Li M; Li G; Wetzstein MM; Herasevich V; Gajic O; Benzo RP
    Respir Med; 2011 Oct; 105(10):1501-6. PubMed ID: 21576012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of statistical analysis in open extension studies.
    Yazici Y; Yazici H
    J Rheumatol; 2006 Feb; 33(2):437; author reply 437-8. PubMed ID: 16465682
    [No Abstract]   [Full Text] [Related]  

  • 32. Pros and cons of pragmatic clinical trials.
    Lurie JD; Morgan TS
    J Comp Eff Res; 2013 Jan; 2(1):53-8. PubMed ID: 24236521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.
    Mack ME; Hsia E; Aletaha D
    Arthritis Rheumatol; 2017 Mar; 69(3):518-528. PubMed ID: 27696724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pragmatism in practice: lessons learned during screening and enrollment for a randomised controlled trial in rural northern Ethiopia.
    Molla M; Negussie H; Ngari M; Kivaya E; Njuguna P; Enqueselassie F; Berkley JA; Davey G
    BMC Med Res Methodol; 2018 Mar; 18(1):26. PubMed ID: 29514613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies.
    Srikanthan A; Vera-Badillo F; Ethier J; Goldstein R; Templeton AJ; Ocana A; Seruga B; Amir E
    Cancer Treat Rev; 2016 Feb; 43():67-73. PubMed ID: 26827694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences.
    Oude Rengerink K; Kalkman S; Collier S; Ciaglia A; Worsley SD; Lightbourne A; Eckert L; Groenwold RHH; Grobbee DE; Irving EA;
    J Clin Epidemiol; 2017 Sep; 89():173-180. PubMed ID: 28502808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes from the Patient Perspective Workshop at OMERACT 6.
    Kirwan J; Heiberg T; Hewlett S; Hughes R; Kvien T; Ahlmèn M; Boers M; Minnock P; Saag K; Shea B; Suarez Almazor M; Taal E
    J Rheumatol; 2003 Apr; 30(4):868-72. PubMed ID: 12672218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shouldn't standard rheumatology clinical care be evidence-based rather than eminence-based, eloquence-based, or elegance-based?
    Pincus T; Tugwell P
    J Rheumatol; 2007 Jan; 34(1):1-4. PubMed ID: 17216670
    [No Abstract]   [Full Text] [Related]  

  • 39. Steroids and myocardial infarction in rheumatoid arthritis.
    Russell AS
    J Rheumatol; 2005 Jan; 32(1):195-6; author reply 196-7. PubMed ID: 15630751
    [No Abstract]   [Full Text] [Related]  

  • 40. Steroids for rheumatoid arthritis: the honeymoon revisited (once again).
    Caplan L; Russell AS; Wolfe F
    J Rheumatol; 2005 Oct; 32(10):1863-5. PubMed ID: 16206335
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.